NovaBridge Biosciences (NBP)
Nasdaq: NBP · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2019
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Report filed | Apr 7, 2026 | Apr 3, 2025 | Apr 30, 2024 | May 1, 2023 | Apr 29, 2022 | Apr 28, 2021 | Apr 29, 2020 | · |
| Revenue | · | · | 632r | -1,551r | 13,813 | 236,424 | 4,309 | · |
| Cost of revenue | · | · | · | 3,949 | 7,286 | · | · | · |
| Research and development | 62,905 | 21,770 | 21,448r | 22,547r | 190,340 | 150,910 | 120,718 | · |
| General and administrative | 31,364 | 29,656 | 28,160r | 28,980r | 141,221 | 61,672 | 94,021 | · |
| Total operating expenses | 94,269 | 51,426 | 72,649 | 51,527 | · | · | · | · |
| Operating income | -94,269 | -51,426 | -72,017 | -53,078 | · | · | · | · |
| Interest expense | · | · | 102 | 1 | 0 | 147 | 430 | · |
| Interest and investment income | 7,611 | 7,486 | 9,294r | 4,954r | 3,348 | 3,713 | 4,391 | · |
| Share of profit of equity-method investments | · | -1,038 | -11,404r | -64,707r | -57,729 | -16,642 | · | · |
| Other income (expense), net | -1,682 | -4,718 | -8,090r | -28,269r | 13,050 | 63,278 | -2,902 | · |
| Income before income taxes | -88,340 | -49,696 | -82,217r | -141,100r | -366,365 | 74,044 | -208,560 | · |
| Income tax expense | 0 | 0 | 0 | 103r | -495 | 1,874 | · | · |
| Income from continuing operations | -46,269 | -49,696 | -82,217r | -141,203r | -325,034 | 23,842 | -210,430 | · |
| Income from discontinued operations | 0 | 27,466 | -125,512 | -229,850 | · | · | · | · |
| Net income including non-controlling interests | -88,340 | -22,230 | -207,729 | · | · | · | · | · |
| Net income to non-controlling interests | -42,071 | · | · | · | · | · | · | · |
| Net income | -46,269 | -22,230 | -207,729r | -371,053r | -365,870 | 72,170 | -208,560 | · |
| Net income to common shareholders | · | · | -206,439 | -363,526 | -365,870 | 72,170 | -213,308 | · |
| Earnings per share, basic | -0.21 | -0.12 | -1.09r | -1.96r | -2.09 | 0.54 | -28.90 | · |
| Earnings per share, diluted | -0.21 | -0.12 | -1.09r | -1.96r | -2.09 | 0.46 | -28.90 | · |
| Earnings per share, basic and diluted | · | · | · | · | · | · | -28.90 | · |
| Weighted average shares, basic | 220,258,932 | 186,728,372 | 191,423,850 | 189,787,292 | 174,707,055 | 134,158,824 | 7,381,230 | 6,529,092 |
| Weighted average shares, diluted | 220,258,932 | 186,728,372 | 191,423,850 | 189,787,292 | 174,707,055 | 157,231,652 | 7,381,230 | 6,529,092 |
| Weighted average shares, basic and diluted | · | · | · | · | · | · | 7,381,230 | 6,529,092 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:Revenues
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfRevenueResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestShare of profit of equity-method investments its share of companies it partly owns
us-gaap:IncomeLossFromEquityMethodInvestmentsOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitIncome from continuing operations profit from the businesses it keeps
us-gaap:IncomeLossFromContinuingOperationsIncome from discontinued operations profit or loss from businesses it sold or closed
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income to non-controlling interests the share that belongs to minority holders
us-gaap:NetIncomeLossAttributableToNoncontrollingInterestNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted